{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:30:56Z","timestamp":1792765856562,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Vancomycin-resistant enterococcus (VRE) is an important cause of infection in immunocompromised populations. Few studies have described the characteristics of<jats:italic>vanB<\/jats:italic>VRE infection. We sought to describe the epidemiology, treatment and outcomes of VRE bloodstream infections (BSI) in a<jats:italic>vanB<\/jats:italic>predominant setting in malignant hematology and oncology patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review was performed at two large Australian centres and spanning a 6-year period (2008\u20132014). Evaluable outcomes were intensive care admission (ICU) within 48\u2009h of BSI, all-cause mortality (7 and 30\u2009days) and length of admission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 106 BSI episodes were observed in 96 patients, predominantly<jats:italic>Enterococcus faecium vanB<\/jats:italic>(105\/106, 99%). Antibiotics were administered for a median of 17\u2009days prior to BSI, and 76\/96 (79%) were neutropenic at BSI onset. Of patients screened before BSI onset, 49\/72 (68%) were found to be colonised. Treatment included teicoplanin (59), linezolid (6), daptomycin (2) and sequential\/multiple agents (21). Mortality at 30-days was 31%. On multivariable analysis, teicoplanin was not associated with mortality at 30\u2009days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>VRE BSI in a<jats:italic>vanB<\/jats:italic>endemic setting occurred in the context of substantive prior antibiotic use and was associated with high 30-day mortality. Targeted screening identified 68% to be colonised prior to BSI. Teicoplanin therapy was not associated with poorer outcomes and warrants further study for<jats:italic>vanB<\/jats:italic>VRE BSI in cancer populations.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-020-04952-5","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T12:53:18Z","timestamp":1584535998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting"],"prefix":"10.1186","volume":"20","author":[{"given":"Ouli","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bajel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby P.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon J.","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"issue":"4","key":"4952_CR1","doi-asserted-by":"publisher","first-page":"E181","DOI":"10.1111\/1469-0691.12132","volume":"19","author":"AL Cheah","year":"2013","unstructured":"Cheah AL, Spelman T, Liew D, Peel T, Howden BP, Spelman D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect. 2013;19(4):E181\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"4952_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/1471-2334-14-353","volume":"14","author":"AL Cheah","year":"2014","unstructured":"Cheah AL, Peel T, Howden BP, Spelman D, Grayson ML, Nation RL, et al. Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia. BMC Infect Dis. 2014;14:353.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"4952_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/infdis\/172.4.993","volume":"172","author":"DK Shay","year":"1995","unstructured":"Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995;172(4):993\u20131000.","journal-title":"J Infect Dis"},{"issue":"6","key":"4952_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/cid\/cis550","volume":"55","author":"J Vydra","year":"2012","unstructured":"Vydra J, Shanley RM, George I, Ustun C, Smith AR, Weisdorf DJ, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(6):764\u201370.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4952_CR5","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1128\/AAC.06299-11","volume":"56","author":"K Hayakawa","year":"2012","unstructured":"Hayakawa K, Marchaim D, Martin ET, Tiwari N, Yousuf A, Sunkara B, et al. Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia. Antimicrob Agents Chemother. 2012;56(5):2452\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4952_CR6","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.3109\/10428194.2014.896007","volume":"55","author":"MJ Satlin","year":"2014","unstructured":"Satlin MJ, Soave R, Racanelli AC, Shore TB, van Besien K, Jenkins SG, et al. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014;55(12):2858\u201365.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4952_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/430909","volume":"41","author":"CA DiazGranados","year":"2005","unstructured":"DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41(3):327\u201333.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4952_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1086\/649020","volume":"31","author":"AM Butler","year":"2010","unstructured":"Butler AM, Olsen MA, Merz LR, Guth RM, Woeltje KF, Camins BC, et al. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp Epidemiol. 2010;31(1):28\u201335.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"4952_CR9","volume-title":"2019: third Australian report on antimicrobial use and resistance in human health","author":"AURA","year":"2019","unstructured":"AURA. 2019: third Australian report on antimicrobial use and resistance in human health. Australian Commission on Safety and Quality in Health Care: Sydney; 2019."},{"issue":"12","key":"4952_CR10","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/jac\/dkw319","volume":"71","author":"RE Mendes","year":"2016","unstructured":"Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN. Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. J Antimicrob Chemother. 2016;71(12):3453\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"4952_CR11","unstructured":"European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2016. Annual report of the European antimicrobial resistance surveillance network (EARS-net). Stockholm: ECDC; 2017."},{"issue":"10","key":"4952_CR12","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1128\/JCM.00211-16","volume":"54","author":"ML Faron","year":"2016","unstructured":"Faron ML, Ledeboer NA, Buchan BW. Resistance mechanisms, epidemiology, and approaches to screening for Vancomycin-resistant Enterococcus in the health care setting. J Clin Microbiol. 2016;54(10):2436\u201347.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"4952_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1128\/CMR.13.4.686","volume":"13","author":"Y Cetinkaya","year":"2000","unstructured":"Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000;13(4):686\u2013707.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"4952_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1469-0691.2011.03591.x","volume":"18","author":"T Peel","year":"2012","unstructured":"Peel T, Cheng AC, Spelman T, Huysmans M, Spelman D. Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia. Clin Microbiol Infect. 2012;18(4):388\u201394.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"4952_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1600-0609.2007.00911.x","volume":"79","author":"LJ Worth","year":"2007","unstructured":"Worth LJ, Thursky KA, Seymour JF, Slavin MA. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol. 2007;79(3):226\u201333.","journal-title":"Eur J Haematol"},{"issue":"12","key":"4952_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jclinepi.2006.01.016","volume":"59","author":"JC McGregor","year":"2006","unstructured":"McGregor JC, Perencevich EN, Furuno JP, Langenberg P, Flannery K, Zhu J, et al. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol. 2006;59(12):1266\u201373.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"4952_CR17","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","volume":"101","author":"RC Bone","year":"1992","unstructured":"Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM consensus conference committee. American College of Chest Physicians\/Society of Critical Care Medicine. Chest. 1992;101(6):1644\u201355.","journal-title":"Chest."},{"issue":"5","key":"4952_CR18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/tid.12120","volume":"15","author":"Y Kang","year":"2013","unstructured":"Kang Y, Vicente M, Parsad S, Brielmeier B, Pisano J, Landon E, et al. Evaluation of risk factors for vancomycin-resistant Enterococcus bacteremia among previously colonized hematopoietic stem cell transplant patients. Transpl Infect Dis. 2013;15(5):466\u201373.","journal-title":"Transpl Infect Dis"},{"key":"4952_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/1471-2334-13-504","volume":"13","author":"SY Cho","year":"2013","unstructured":"Cho SY, Lee DG, Choi SM, Kwon JC, Kim SH, Choi JK, et al. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infect Dis. 2013;13:504.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"4952_CR20","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00520-010-1038-z","volume":"19","author":"S Kraft","year":"2011","unstructured":"Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer. 2011;19(12):1969\u201374.","journal-title":"Support Care Cancer"},{"issue":"6","key":"4952_CR21","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/jac\/dky075","volume":"73","author":"T Gouliouris","year":"2018","unstructured":"Gouliouris T, Warne B, Cartwright EJP, Bedford L, Weerasuriya CK, Raven KE, et al. Duration of exposure to multiple antibiotics is associated with increased risk of VRE bacteraemia: a nested case-control study. J Antimicrob Chemother. 2018;73(6):1692\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4952_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1086\/502016","volume":"23","author":"R Husni","year":"2002","unstructured":"Husni R, Hachem R, Hanna H, Raad I. Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer. Infect Control Hosp Epidemiol. 2002;23(2):102\u20133.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"4952_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1086\/666331","volume":"33","author":"JA McKinnell","year":"2012","unstructured":"McKinnell JA, Kunz DF, Chamot E, Patel M, Shirley RM, Moser SA, et al. Association between vancomycin-resistant enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol. 2012;33(7):718\u201324.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"4952_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/bmt.2014.150","volume":"49","author":"M Tavadze","year":"2014","unstructured":"Tavadze M, Rybicki L, Mossad S, Avery R, Yurch M, Pohlman B, et al. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(10):1310\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"4952_CR25","volume-title":"Han SB","author":"KS Bae","year":"2018","unstructured":"Bae KS, Shin JA, Kim SK. Han SB. Lee DG, et al. Enterococcal bacteremia in febrile neutropenic children and adolescents with underlying malignancies, and clinical impact of vancomycin resistance. Infection: Lee JW; 2018."},{"issue":"3","key":"4952_CR26","first-page":"182","volume":"58","author":"SH Han","year":"2009","unstructured":"Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, Kim CO, et al. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome. J Inf Secur. 2009;58(3):182\u201390.","journal-title":"J Inf Secur"},{"key":"4952_CR27","volume-title":"Cohen N","author":"M Kamboj","year":"2018","unstructured":"Kamboj M. Cohen N. Kerpelev M, Jakubowski A, Sepkowitz KA, et al. Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant: Huang YT; 2018."},{"issue":"12","key":"4952_CR28","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/cid\/cix232","volume":"64","author":"BJ Webb","year":"2017","unstructured":"Webb BJ, Healy R, Majers J, Burr Z, Gazdik M, Lopansri B, et al. Prediction of bloodstream infection due to Vancomycin-resistant Enterococcus in patients undergoing leukemia induction or hematopoietic stem-cell transplantation. Clin Infect Dis. 2017;64(12):1753\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4952_CR29","first-page":"38","volume":"77","author":"TJ MacAllister","year":"2018","unstructured":"MacAllister TJ, Stohs E, Liu C, Bryan A, Whimbey E, Phipps A, et al. 10-year trends in vancomycin-resistant enterococci among allogeneic hematopoietic cell transplant recipients. J Inf Secur. 2018;77(1):38\u201346.","journal-title":"J Inf Secur"},{"key":"4952_CR30","volume-title":"2016: first Australian report on antimicrobial use and resistance in human health","author":"AURA","year":"2016","unstructured":"AURA. 2016: first Australian report on antimicrobial use and resistance in human health. Australian Commission on Safety and Quality in Health Care: Sydney; 2016."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-04952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-04952-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-04952-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T10:53:04Z","timestamp":1722595984000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-04952-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4952"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-04952-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]},"assertion":[{"value":"25 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by Human Research Ethics Committees at the Royal Melbourne Hospital (reference number: QA2015054) and Peter MacCallum Cancer Centre (reference number: 16\/35R). All data was anonymised before use in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}